AdaptHealth Corp. (AHCO) Made Misleading Statements Regarding its Business Prospects    On July 8, 2019, DFB, a special purpose acquisition company, announced it had entered into a definitive merger agreement

Iterum Therapeutics plc (ITRM) Made Misleading Statements Regarding its Drug Candidate     Iterum is developing sulopenem, an anti-infective compound with oral and intravenous formulations that is in Phase III clinical

Zymergen Inc. (ZY) Made Misstatements Regarding its Business Prospects Zymergen held its IPO on April 23, 2021, raising approximately $530.1 million.  On August 3, 2021, Zymergen issued a business update

Kanzhun Limited (BZ) Misled the Investing Public Regarding Its Cybersecurity Risks    On July 5, 2021, Kanzhun announced that it was “subject to cybersecurity review by” the Cyberspace Administration of

Orphazyme A/S (ORPH) Misstated the Efficacy of its Drug Arimoclomal in its IPO Offering Documents      Orphazyme held a public offering in September 2020 based on negligently prepared offering documents. 

James River Group Holdings, Ltd. (JRVR) Misled the Investing Public Regarding the Impact of Uber on the Company’s Reserves   In 2014, James River entered into a novel agreement with

Home Point Capital Inc. (HMPT) Made Misstatements in its IPO Offering Documents According to the class action complaint asserting claims under the Securities Act of 1933, Home Point conducted its

Oatly Group AB (OTLY) Made Misleading Statements in its Registration Statement in Connection with its Initial Public Offering   Oatly held its initial public offering (“IPO”) on May 20, 2021,

Tarena International, Inc. (TEDU) Made Misstatements Regarding its Accounting Practices      During the class period, defendants made false and misleading statements and/or failed to disclose that: (1) certain employees were